Dermatology Looks Simple. It Isn't.
Regulatory strategy for dermatology — where generics face the hardest bioequivalence in pharma and the endpoint is often a photograph.
A Cream Is a Delivery System Disguised as a Simple Product.
A topical drug has to get the right amount of active through the skin barrier and into the target layer — and the vehicle that carries it is as consequential as the molecule. Formulation, release, and permeation are regulated questions, and the placebo vehicle itself can have a real effect that muddies the read.
Above the topicals sit systemic biologics and orals borrowed from immunology, and beneath them a new frontier of topical gene therapy for rare skin disease. We build dermatology programs that respect how hard the science under the surface really is — across topical, systemic, and everything between.
In a topical product, the formulation that delivers the drug to the skin is a regulated object in its own right.
The Hardest Bioequivalence in Pharma Is Proven in Layers.
You cannot measure a topical drug's blood level the way you would an oral. So the FDA built a layered, weight-of-evidence approach to topical bioequivalence — and each layer has to hold for a generic or a reformulation to clear.
Formulation Sameness — Q1 / Q2 / Q3
The same inactive ingredients (Q1), in the same amounts (Q2), arranged in the same microstructure and physical state (Q3) — the foundation the whole case rests on.
In Vitro Performance — IVRT & IVPT
In vitro release testing and in vitro permeation testing across human skin, showing the drug leaves the vehicle and crosses the barrier the same way.
Clinical or PK Confirmation
A comparative clinical endpoint or, where feasible, a maximal-usage pharmacokinetic study — the confirmation the division wants when the earlier layers cannot fully carry it.
Miss one layer and the file falls. The art is knowing which layers the specific product needs — and building the case so a comparative clinical endpoint study, the most expensive layer, is only used where the science genuinely requires it.
From Topical Vehicles to Systemic Biologics to Topical Gene Therapy.
Dermatology now spans the oldest formulation science and the newest genetic medicine — with a shared reliance on visual, scored endpoints.
Psoriasis
The dermatology proving ground, where topical, oral, and IL-17/IL-23 biologic classes compete on PASI 90/100 and IGA clearance.
Atopic Dermatitis
Where itch and EASI endpoints, type-2 biologics, and topical JAK inhibitors made eczema one of the busiest spaces in the field.
Acne & Rosacea
Where inflammatory and non-inflammatory lesion counts and IGA anchor a topical-heavy, formulation-driven regulatory pathway.
Vitiligo & Pigmentary
Where repigmentation endpoints and standardized imaging opened a newly active area after the first approved therapies.
Rare Skin Disease
Epidermolysis bullosa and other genodermatoses, where topical gene therapy and orphan flexibility opened once-untreatable disease.
Skin Cancer
Melanoma and non-melanoma skin cancer, reviewed as oncology, where topical and systemic approaches meet the OCE playbook.
PASI, EASI, and IGA are scored by eye — so rater training and standardized imaging are part of the evidence.
When the Endpoint Is a Visual Score, Consistency Is the Whole Game.
Most dermatology endpoints are clinician-assessed scores — PASI, EASI, IGA, lesion counts, repigmentation. That makes rater training, standardized photography, and central reading part of the regulatory package, and the placebo vehicle response a real threat to a clean read.
We build the endpoint and imaging strategy the division expects — validated instruments, rater consistency, and vehicle-controlled designs — and the 505(b)(2) or biologic pathway that fits the asset, so the visual signal survives scrutiny.
Dermatology Rewards Sponsors Who Don't Underestimate It.
The topical formulation, the visual endpoint, and the vehicle effect each look manageable and each sink programs that treated them lightly. The advantage goes to teams that engineer for all three.
microstructure sameness is where topical generics most often fail — the physical arrangement of the formulation, not just its ingredients.
reformulations and new delivery systems make the (b)(2) pathway a workhorse in dermatology — bridging to prior findings the right way is the skill.
The placebo vehicle can have a real therapeutic effect — a design that ignores it invites a failed or uninterpretable trial.
Six Failure Modes We Are Brought In to Prevent.
Most come from treating a topical product as if it were a simple one.
A topical BE case missing a layer
Bringing Q1/Q2 sameness and IVRT data without the Q3 microstructure or IVPT evidence the weight-of-evidence standard requires.
The vehicle effect designed out too late
A trial where the placebo vehicle performs so well the drug can't separate — discovered after the pivotal, not before it.
Rater and imaging inconsistency
Visual endpoints scored without the rater training, standardization, and central reading that keep a subjective score defensible.
The wrong pathway for the asset
Filing a reformulation as a full NDA, or misjudging a 505(b)(2) bridge, and paying for evidence the pathway didn't require.
Systemic exposure underestimated
Skipping the maximal-usage PK work that even topical products need when systemic absorption and safety come into question.
Rare-disease derm treated generically
An epidermolysis bullosa or genodermatosis program that missed the orphan, natural-history, and gene-therapy strategy the indication needed.
Dermatology Regulatory Leadership That Respects the Science Under the Skin.
Our dermatology leads have built topical bioequivalence cases, taken systemic biologics through visual-endpoint trials, and navigated 505(b)(2) and rare-skin-disease pathways.
"In dermatology the simplest-looking product hides the hardest science. We build for the topical formulation, the visual endpoint, and the vehicle effect together — because any one of them can sink the file."
The discipline we bring across psoriasis, atopic dermatitis, acne, vitiligo, and rare skin disease.
Developing a Dermatology Therapy? Don't Let a Simple-Looking Product Hide a Hard File.
Bring senior dermatology regulatory leadership in early — while the formulation, endpoints, and bioequivalence strategy are still yours to shape.
Senior-led. Embedded in your team. No junior hand-offs.